CRI Funded Scientists

Nina Bhardwaj, MD, PhD, Clinical Accelerator Investigator

Icahn School of Medicine at Mount Sinai

Area of Research: Bladder Cancer, Cáncer de mama, Head and Neck Cancer, Kidney Cancer, Lymphoma, Melanoma, Cáncer de próstata, Sarcoma, Skin Cancer

Dr. Nina Bhardwaj is a professor of medicine, hematology, and medical oncology, and a professor of urology at the Icahn School of Medicine at Mount Sinai. She is currently one of the two study chairs of the clinical trial “A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers” (NCT02643303).

This study examines combinations of two checkpoint immunotherapies, plus an immune-stimulating adjuvant, in a wide variety of patients diagnosed with breast cancersarcomahead and neck cancerlymphomamelanomabladder cancerkidney cancerprostate cancer, among other types of cancer. One checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the other, tremelimumab, blocks the CTLA-4 pathway. The adjuvant, poly ICLC, promotes an immune system response similar to that of vaccines.

Additional investigators working on  this trial include:

  • Craig Slingluff Jr., MD, University of Virginia Health (Other study chair)
  • Danae Hamouda, MD, Toledo University
  • Elizabeth Gaughan, MD, University of Virginia Health
  • Igor Puzanov, MD, Roswell Park Cancer Institute
  • Keisuke Shirai MD, Dartmouth University
  • Megan Kruse, MD, Cleveland Clinic
  • Michael Lowe, MD, Emory University

Projects and Grants

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers (NCT02643303)

Icahn School of Medicine at Mount Sinai | Bladder Cancer, Breast Cancer, Head and Neck Cancer, Kidney Cancer, Lymphoma, Melanoma, Other Cancer, Prostate Cancer, Sarcoma, Skin Cancer | 2015

Analysis of immune responses induced by in situ, autologous therapeutic vaccination against solid cancers with intratumoral hiltonol (Poly-ICLC).

Icahn School of Medicine at Mount Sinai | Melanoma, Sarcoma | 2016

The mutation-derived tumor antigen landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy

Icahn School of Medicine at Mount Sinai | Bladder Cancer | 2015

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.